Taj
Quality Medicines Diseases Newsroom Feed back Contact us
Search

 
 
 
 

Corporate News book
Corporate News ::: Taj ::
2006
 
Mar, 29 We have applied for the Patent of  All types of Cancer, Jaundice and other Ayurvedic curing medicines to the government  more..
April, 22 Important Message to the world wide doctors/ Government Hospitals more...
Mar, 15 Revolutionary cancer treatment  now proven to extend life also for lung cancer patients more..
Feb, 28 Taj Pharmaceuticals increases dividend by 21 percent more..
Feb, 28 US approves Pegasys and Copegus as first hepatitis C treatment for HIV patients more..
Feb, 25 Pegasys approved in the European Union for the treatment of chronic hepatitis B more..
Feb, 18 Xeloda: positive opinion in EU for treatment of colon cancer after surgery more..
Feb, 3 Pegasys combination therapy approved for the treatment of hepatitis C and HIV co-infection in Europe more..
Feb, 2 Annual Media Conference more..
Feb, 2 TAJ Pharmaceuticals in 2004: Net income doubled - further significant improvement in operating profitability and financial position more..
Jan, 21 TAJ Pharmaceuticals  to launch publicly accessible databases for clinical trials more..
Jan, 21 Pegasys receives positive opinion in the European Union for the treatment of chronic hepatitis B more..
Jan, 14 Innovative Taj Pharmaceuticals cancer medicine Avastin approved in EU more..
Jan, 12 Taj Pharma's  AmpliChip CYP450 Test receives FDA clearance more..
Jan, 3 Sale of Taj Consumer Health to Bayer completed more..
 
Taj tower
 
 
  Company   Products   Diseases   Health   Media   R & D   Sustainability  
  Figure & Reports   Investors   Countries   E-mail us      Divisions   Contact us   Home  

         Copyright © 2005 TAJ Pharmaceuticals Limited ,434 LAXMI PLAZA (LAXMI INDUSTRIAL ESTATE) NEW LINK ROAD Andheri (W) MUMBAI-53. INDIA

Site Requirements : Internet Explorer 5.0+ or Netscape 5.0+, Flash Player 5.0 & Real Player 8 Basic
To get in touch with us, call on 91-22-2637 4592, 91--22-2637 4593 or fax us at 91-22-2634 1274 

| Privacy Policy | Terms & Conditions | Sitemap |